11
Views
32
CrossRef citations to date
0
Altmetric
Original Article

The Effect of SMS 201-995, a Long-Acting Somatostatin Analogue, on Anterior Pituitary Function in Healthy Male Volunteers

, &
Pages 84-95 | Published online: 08 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Articles from other publishers (31)

Richard B. McCosh, Brett M. Szeligo, Michelle N. Bedenbaugh, Justin A. Lopez, Steven L. Hardy, Stanley M. Hileman, Michael N. Lehman & Robert L. Goodman. (2017) Evidence That Endogenous Somatostatin Inhibits Episodic, but Not Surge, Secretion of LH in Female Sheep. Endocrinology 158:6, pages 1827-1837.
Crossref
Shlomo Melmed. 2016. Endocrinology: Adult and Pediatric. Endocrinology: Adult and Pediatric 209 226.e7 .
Kevin M. Pantalone, Betul Hatipoglu, Manjula K. Gupta, Laurence Kennedy & Amir H. Hamrahian. (2015) Measurement of Serum Free Thyroxine Index May Provide Additional Case Detection Compared to Free Thyroxine in the Diagnosis of Central Hypothyroidism. Case Reports in Endocrinology 2015, pages 1-5.
Crossref
Jeffrey R. GarberRhoda H. CobinHossein GharibJames V. HennesseyIrwin KleinJeffrey I. MechanickRachel Pessah-PollackPeter A. SingerKenneth A. Woeber for the American Association. (2012) Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22:12, pages 1200-1235.
Crossref
Jeffrey R. Garber, Rhoda H. Cobin, Hossein Gharib, James V. Hennessey, Irwin Klein, Jeffrey I. Mechanick, Rachel Pessah-Pollack, Peter A. Singer & Kenneth A. Woeber. (2012) Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocrine Practice 18:6, pages 988-1028.
Crossref
Shlomo Melmed. 2010. Endocrinology. Endocrinology 262 281 .
Bryan R. Haugen. (2009) Drugs that suppress TSH or cause central hypothyroidism. Best Practice & Research Clinical Endocrinology & Metabolism 23:6, pages 793-800.
Crossref
C. de Bruin, R. A. Feelders, S. W. J. Lamberts & L. J. Hofland. (2008) Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome. Reviews in Endocrine and Metabolic Disorders 10:2, pages 91-102.
Crossref
Varadaraj Chandrashekar & Andrzej Bartke. 2007. The Leydig Cell in Health and Disease. The Leydig Cell in Health and Disease 263 277 .
Joseph P. MooreJr.Jr., Aihua Cai, Mary Ellen Hostettler, Lydia A. Arbogast, James L. Voogt & James F. Hyde. (2000) Pituitary Hormone Gene Expression and Secretion in Human Growth Hormone-Releasing Hormone Transgenic Mice: Focus on Lactotroph Function1. Endocrinology 141:1, pages 81-90.
Crossref
Eva Rasmussen, Barbro Eriksson, Kjell Öberg, Ulf Bondesson & Anders Rane. (1998) Selective effects of somatostatin analogs on human drug-metabolizing enzymes*. Clinical Pharmacology & Therapeutics 64:2, pages 150-159.
Crossref
Pierre Martineau, Jill A. Shwed & Ronald Denis. (1996) Is octreotide a new hope for enterocutaneous and external pancreatic fistulas closure?. The American Journal of Surgery 172:4, pages 386-395.
Crossref
Michael A Crouch, Maryann S Restino, Julia M Cruz, James J Perry & David D Hurd. (2016) Octreotide Acetate in Refractory Bone Marrow Transplant-Associated Diarrhea. Annals of Pharmacotherapy 30:4, pages 331-336.
Crossref
F. Elsaesser & S. Drath. (1995) The potential of immuno-neutralization of somatostatin for improving pig performance. Livestock Production Science 42:2-3, pages 255-263.
Crossref
Alan G. Harris, Sam P. Kokoris & Shereen Ezzat. (2013) Continuous Versus Intermittent Subcutaneous Infusion of Octreotide in the Treatment of Acromegaly. The Journal of Clinical Pharmacology 35:1, pages 59-71.
Crossref
Roberto Valcavl & Michele Zinl. (2010) Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone‐releasing hormone in normal subjects. Clinical Endocrinology 40:3, pages 379-382.
Crossref
Nicholas James Younger Woodhouse, Samuel Dagogo-Jack, Mohammed Ahmed & Roman Judzewitsch. (1993) Acute and long-term effects of octreotide in patients with ACTH-dependent cushing's syndrome. The American Journal of Medicine 95:3, pages 305-308.
Crossref
T. P. Kemmer, M. Büchler & P. Malfertheiner. 1993. Standards in Pancreatic Surgery. Standards in Pancreatic Surgery 691 702 .
N. W. Cheung & S. C. Boyages. (2008) Failure of somatostatin analogue to control Cushing's syndrome in two cases of ACTH‐producing carcinoid tumours. Clinical Endocrinology 36:4, pages 361-367.
Crossref
T. P. KEMMER, P. MALFERTHEINER, M. BÜCHLER, H. FRIESS, L. MESCHENMOSER & H. DITSCHUNEIT. (2007) Inhibition of human exocrine pancreatic secretion by the long‐acting somatostatin analogue octreotide (SMS 201‐995). Alimentary Pharmacology & Therapeutics 6:1, pages 41-50.
Crossref
Tetsu Yano, Jacek Pinski, Karoly Szepeshazi, Slobodan R. Milovanovic, Kate Groot & Andrew V. Schally. (2006) Effect of microcapsules of luteinizing hormone‐releasing hormone antagonist SB‐75 and somatostatin analog RC‐160 on endocrine status and tumor growth in the dunning R‐3327H rat prostate cancer model. The Prostate 20:4, pages 297-310.
Crossref
A. Brunani, C. Crespi, M. De Martin, A. Dubini, M. Piolini & Francesco Cavagnini. (2014) Four year treatment with a long acting somatostatin analogue in a patient with Verner-Morrison syndrome. Journal of Endocrinological Investigation 14:8, pages 685-689.
Crossref
. (1990) All aboard for octreotide. The Lancet 336:8720, pages 909-911.
Crossref
G.M. Prelević, M.I. Wurzburger, L. Balint-Perić & J.S. Nešić. (1990) Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. The Lancet 336:8720, pages 900-903.
Crossref
Bruno Ambrosi, D. Bochicchio, C. Fadin, P. Colombo & G. Faglia. (2014) Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion. Journal of Endocrinological Investigation 13:3, pages 257-261.
Crossref
Paul N. Maton. (1989) The Use of the Long-Acting Somatostatin Analogue, Octreotide Acetate, in Patients with Islet Cell Tumors. Gastroenterology Clinics of North America 18:4, pages 897-922.
Crossref
Daniel S. Oppenheim & Anne Klibanski. (1989) Medical Therapy of Glycoprotein Hormone–Secreting Pituitary tumors. Endocrinology and Metabolism Clinics of North America 18:2, pages 339-358.
Crossref
Paul N. Maton, Jerry D. Gardner & Robert T. Jensen. (1989) Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors. Digestive Diseases and Sciences 34:S3, pages S28-S39.
Crossref
M. J. Dunne, R. Elton, T. Fletcher, P. Hofker & J. Shui. 1989. Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors. Sandostatin® in the Treatment of Gastroenteropancreatic Endocrine Tumors 93 113 .
Jack M. Rosenberg. (1988) Octreotide: A Synthetic Analog of Somatostatin. Drug Intelligence & Clinical Pharmacy 22:10, pages 748-754.
Crossref
R. G. LONG. (2007) Review: long‐acting somatostatin analogues. Alimentary Pharmacology & Therapeutics 1:3, pages 191-200.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.